Please login to the form below

Not currently logged in
Email:
Password:

insulin aspart

This page shows the latest insulin aspart news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk preps for speedy oral GLP-1 drug filing

Novo Nordisk preps for speedy oral GLP-1 drug filing

10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone. ... Novo’s CEO Lars Fruergaard Jørgensen. New fast-acting mealtime insulin Fiasp (insulin aspart),

Latest news

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    The dual-therapy works to reduce high blood glucose while enhancing glucose-dependent insulin secretion and reducing glucagon release. ... Meanwhile, Novo Nordisk looks set to add Fiasp (insulin aspart) to its diabetes drug stable, as the fast-acting

  • Novo Nordisk's Tresiba gaining ground in basal insulin market Novo Nordisk's Tresiba gaining ground in basal insulin market

    Sales of Novo Nordisk's new basal insulin product Tresiba have started to gather momentum since its US launch in January, rising three-fold in the first half of the year. ... Nevertheless, the strong sales performance for Tresiba and other new insulin

  • Tresiba safer than insulin glargine, says Novo Nordisk Tresiba safer than insulin glargine, says Novo Nordisk

    Moreover, it could also differentiate Tresiba from biosimilar copies of Sanofi's drug that are starting to reach the market and threaten to disrupt the basal insulin category. ... Last October however the Danish drugmaker finally won US approval for

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    Long-acting basal insulin Tresiba (insulin degludec) and combination drug Ryzodeg (insulin degludec and insulin aspart) will now be able to compete head-to-head in the market with Sanofi's ... that the drug – along with Ryzodeg and Xultophy (insulin

  • Novo brings Xultophy to third European market Novo brings Xultophy to third European market

    We do see that some patients that have been on both an insulin and Victoza, some of those may be converted to get it in one injection. ... US regulators dealt the company a major blow in February 2013 when marketing applications for Tresiba and Ryzodeg,

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics